The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)
Abstract
BACKGROUND: Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascular/metabolic risk profile than current immunosuppressants. METHODS: Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT and BENEFIT-EXT) of belatacept-based regimens in kidney transplant recipients were assessed at month 12. Each study assessed belatacept in more intensive (MI) and less intensive (LI) regimens versus cyclosporine A (CsA). These secondary endpoints included changes in blood pressure, changes in serum lipids, and the incidence of new-onset diabetes after transplant (NODAT). RESULTS: A total of 1209 patients were randomized and transplanted across the two studies. Mean systolic blood pressure was 6 to 9 mm Hg lower and mean diastolic blood pressure was 3 to 4 mm Hg lower in the MI and LI groups versus CsA (P ≤ 0.002) across both studies at month 12. Non-HDL cholesterol was lower in the belatacept groups versus CsA (P<0.01 MI or LI vs. CsA in each study). Serum triglycerides were lower in the belatacept groups versus CsA (P<0.02 MI or LI vs. CsA in each study). NODAT occurred less often in the belatacept groups versus CsA in a prespecified pooled analysis (P<0.05 MI or LI vs. CsA). CONCLUSIONS: At month 12, belatacept regimens were associated with better cardiovascular and metabolic risk profiles, with lower blood pressure and serum lipids and less NODAT versus CsA. The overall profile of belatacept will continue to be assessed over the 3-year trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An additional consideration is that men with CMD, whether characterized by prediabetes, metabolic syndrome, obesity, or T2D, are at increased risk of hypogonadism and testosterone deficiency.1566–1569”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1569]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Diabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Self-citationVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citationManjunath, G., Tighiouart, H., Ibrahim, H., MacLeod, B., Salem, D. N., Griffith, J. L., Coresh, J., Levey, A. S., & Sarnak, M. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02663-3 · Cited by 920
Research works printed but not linked: 1
- 2003, Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations., Am J Kidney Dis, 41, S11
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Prevention of cardiovascular disease in adult recipients of kidney transplants
Jardine, A. G., Gaston, R. S., Fellstrom, B. C., & Holdaas, H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61334-2 · Cited by 281
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Rostaing, L., Vincenti, F., Grinyó, J., Rice, K. M., Bresnahan, B., Steinberg, S., Gang, S., Gaite, L. E., Moal, M.-C., Mondragón-Ramirez, G. A., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12460 · Cited by 197
Self-citationLong-Term Immunosuppression Management: Opportunities and Uncertainties
Wojciechowski, D., & Wiseman, A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15040920 · Cited by 170
Metadata
- Authors
- Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., & Vincenti, F.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Medical College of Wisconsin (US)
- Hospital Clínic de Barcelona (ES)
- Charité – Universitätsmedizin Berlin (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Emory University (US)
- Instituto Nacional de Cardiología (MX)
- University of California, San Francisco (US)
- Corresponding author
- Vanrenterghem, Yves
- Venue
- Transplantation
- Published
- 2011-05-15
- Volume
- 91
- Issue
- 9
- Pages
- 976-983
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1976465544
- Cited by
- 183
- References
- 67
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 10 · 2020: 5 · 2019: 11 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 24 · 2013: 13 · 2012: 24
- FWCI
- 16.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- belatacept, cyclosporine, kidney transplantation, cardiovascular risk, metabolic risk, blood pressure, serum lipids, non-HDL cholesterol, triglycerides, post-transplant diabetes mellitus, calcineurin inhibitors, immunosuppressive regimens, costimulation blockade
- MeSH terms
- Abatacept, Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Immunosuppressive Agents, Lipids, Male, Middle Aged, Risk Factors, Kidney Transplantation, Cyclosporine, Immunoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). https://app.cochat.ai/papers/10.1097/tp.0b013e31820c10eb
- The paper
- Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., & Vincenti, F. (2011). Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation. https://doi.org/10.1097/tp.0b013e31820c10eb
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.